Shopping Cart
- Remove All
Your shopping cart is currently empty
Orticumab
🥰Excellent
Catalog No. T77123Cas No. 1314241-10-5
Alias MLDL1278A
Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis.
Orticumab
Orticumab
🥰Excellent
Purity: 95%
Catalog No. T77123Alias MLDL1278ACas No. 1314241-10-5
Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $413 | In Stock | |
| 5 mg | $1,230 | In Stock | |
| 10 mg | $1,990 | In Stock | |
| 25 mg | $2,950 | In Stock | |
| 50 mg | $3,980 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View MoreBatch Information
Select Batch
Concentration:20.297 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis. |
| In vivo | Methods: Orticumab (10 mg/kg, intraperitoneal injection, once a week for three weeks) was used to treat B6.lpr.ApoE-/- mice (18 weeks old) fed a high-fat diet (HFD) and its therapeutic effect was observed. Results: Orticumab treatment reduced aortic arch atherosclerosis by 42.8% and CD68 macrophage subvalvular plaque staining by 30.5%. [1] |
| Synonyms | MLDL1278A |
| Cas No. | 1314241-10-5 |
| Color | Transparent |
| Appearance | Liquid |
Storage & Solubility Information
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Orticumab | purchase Orticumab | Orticumab cost | order Orticumab | Orticumab in vivo
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.